

## **SpectraCure to the Premier Segment of First North Growth Market**

SpectraCure AB (publ) announces today that Nasdaq has approved the Company's application to move its stock trading to First North Premier Growth Market. The transfer is an important step towards a future listing on Nasdaq Stockholm's main market.

The trade in SpectraCure's shares on First North Premier Growth Market will be initiated on Thursday, October 10, 2019.

"The fact that we are able to move the trade to Premier is an important strategic step in our desire to facilitate institutional and international ownership of SpectraCure and eventually, in the future, a listing on the main list", says Masoud Khayyami, CEO.

The First North Premier Growth Market is a segment targeted to companies that is preparing for a main market listing, with higher disclosure and accounting standards than the regular First North rules. The rules on First North Premier Growth Market corresponds very much to the rules of Nasdaq's main market listing as a regulated marketplace.

SpectraCure reports according to International Financial Reporting Standards, IFRS, a demand for all companies traded on First North Premier Growth Market.

SpectraCure's shareholders do not need to take any action in connection with the listing on First North Premier Growth Market. The share will be traded under the same short name (SPEC) and ISIN code as before.

**For further information, contact:**

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: [ca@gwkapital.se](mailto:ca@gwkapital.se), phone: +46-(8)-503 000 50.

**SpectraCure in short**

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region